Cardiol Therapeutics Inc (CRDL) Stock AnalysisCRDLStock AnalysisCardiol Therapeutics Inc

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Cardiol Therapeutics Inc is a good buy right now due to its current price of $1.94, which is significantly lower than the analyst price target of $11, indicating a potential upside of over 465%. Additionally, the company has shown a year-to-date change of +95.13%, reflecting strong momentum. The main risk is the negative earnings per share of -0.05 reported for Q2 2026, which indicates ongoing losses but is improving compared to previous quarters.